Nutrients (2021) 13(9)
While access remains uneven across commercial plans and Medicare coverage for obesity medicines is still limited, CVS decision signals continued normalization of GLP-1 therapies within mainstream pharmacy benefit design and intensifies competition between Lilly and Novo Nordisk for long-term market leadership in obesity careTop of FormBottom of Form Sources CVS brings back coverage for Lilly's obesity drug Zepbound Reuters May 28, 2026 Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters May 1, 2025
Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use
Improvements in VO2 max, visceral fat reduction, and HbA1c levels often occur when both strategies are implemented together
The side effects of the antidiabetic Ozempic became famous thanks to the star system led, among others, by Elon Musk, and have helped to reduce obesity rates by 2% in the US population between 2020 and 2023
The entire process typically lasts less than an hour, factoring in safety precautions
